The result shows miR-216b introduction downregulates Smad3, increases BCL-2 level, induces chemoresistance to carboplatin with an increase in IC50, and decreases apoptosis (Figure 6A–E), indicating that miR-216b is a potential upstream regulator of BCL-2 in lung cancer. Here, SMAD3 is linked to lung cancer.